Scholarlink

Background <p>Bronchiolitis is the leading cause of lower respiratory tract infections in infants, with respiratory syncytial virus (RSV) as the primary pathogen. Nirsevimab, a long-acting monoclonal antibody, was introduced in Europe in late 2022 for RSV prophylaxis in all infants. In Italy, the 2024–2025 immunization campaign faced regional disparities in implementation. This study aimed to evaluate the impact of Nirsevimab in reducing bronchiolitis diagnoses and hospitalizations in infants during their first RSV season in the Lazio Region.</p> Methods <p>We conducted a retrospective cohort study using data from 29 primary care pediatricians in Lazio. Infants born between August 17, 2024, and March 31, 2025, were included. Bronchiolitis diagnoses were clinically defined, and immunization status was obtained from the regional vaccination registry. We excluded premature infants (&lt; 33 weeks) and those diagnosed before the immunization campaign began on December 9, 2024. To adjust for confounding, we applied inverse probability weighting (IPW) based on a propensity score including demographic and clinical covariates. A negative binomial mixed-effects model was used to estimate incidence rate ratios (IRRs) for bronchiolitis and hospitalizations.</p> Results <p>Among 818 eligible infants, 613 (74.9%) were immunized. A total of 58 bronchiolitis cases were recorded (7.1%), with 6.5% in the immunized group and 8.8% in the non-immunized group. Crude analysis showed a 25.7% risk reduction, while IPW-adjusted analysis indicated a 50.4% reduction (95% CI: 44.4%–55.7%). Hospitalizations occurred in 2.0% of infants, with adjusted analysis showing a 49.1% reduction in hospitalization risk among immunized infants. The immunization campaign’s late start likely limited its full impact, as 40 early-season cases were excluded.</p> Conclusions <p>Nirsevimab immunization significantly reduced the risk of bronchiolitis and related hospitalizations in a real-world primary care setting. This result aligns with previous studies, though it may be underestimated due to the delayed campaign start and inclusion of all-cause bronchiolitis. These findings support early and widespread implementation of Nirsevimab to optimize protection and reduce RSV burden in infants.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Nirsevimab on bronchiolities in pediatric primary care in Lazio Region: an observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月13日

查看全文
  • Daniele Petrone,
  • Ilaria Sani,
  • Valentina De Vittori,
  • Silvana Brenna,
  • Pietro Luigi Rotili,
  • Maria Teresa Fonte,
  • Barbara Baldini Ferroli,
  • Arianna Battaglia,
  • Andrea Battista,
  • Fabio Carlucci,
  • Chiara Castellano,
  • Maria Luisa Criscione,
  • Rita D’agostino,
  • Antonella Ferraro,
  • Angela Germani,
  • Renzo Giovanelli,
  • Cinzia Grassi,
  • Roberta Lanni,
  • Ginevra Lastrucci,
  • Francesca Patriarchi,
  • Annarita La Pera,
  • Alessandra Macari,
  • Serena Mingione,
  • Gabriella Minò,
  • Serena Monaco,
  • Claudia Pontesilli,
  • Marta Porcari,
  • Teresa Rongai,
  • Vincenza Rossomanno,
  • Ermenia Zirletta

摘要

Background

Bronchiolitis is the leading cause of lower respiratory tract infections in infants, with respiratory syncytial virus (RSV) as the primary pathogen. Nirsevimab, a long-acting monoclonal antibody, was introduced in Europe in late 2022 for RSV prophylaxis in all infants. In Italy, the 2024–2025 immunization campaign faced regional disparities in implementation. This study aimed to evaluate the impact of Nirsevimab in reducing bronchiolitis diagnoses and hospitalizations in infants during their first RSV season in the Lazio Region.

Methods

We conducted a retrospective cohort study using data from 29 primary care pediatricians in Lazio. Infants born between August 17, 2024, and March 31, 2025, were included. Bronchiolitis diagnoses were clinically defined, and immunization status was obtained from the regional vaccination registry. We excluded premature infants (< 33 weeks) and those diagnosed before the immunization campaign began on December 9, 2024. To adjust for confounding, we applied inverse probability weighting (IPW) based on a propensity score including demographic and clinical covariates. A negative binomial mixed-effects model was used to estimate incidence rate ratios (IRRs) for bronchiolitis and hospitalizations.

Results

Among 818 eligible infants, 613 (74.9%) were immunized. A total of 58 bronchiolitis cases were recorded (7.1%), with 6.5% in the immunized group and 8.8% in the non-immunized group. Crude analysis showed a 25.7% risk reduction, while IPW-adjusted analysis indicated a 50.4% reduction (95% CI: 44.4%–55.7%). Hospitalizations occurred in 2.0% of infants, with adjusted analysis showing a 49.1% reduction in hospitalization risk among immunized infants. The immunization campaign’s late start likely limited its full impact, as 40 early-season cases were excluded.

Conclusions

Nirsevimab immunization significantly reduced the risk of bronchiolitis and related hospitalizations in a real-world primary care setting. This result aligns with previous studies, though it may be underestimated due to the delayed campaign start and inclusion of all-cause bronchiolitis. These findings support early and widespread implementation of Nirsevimab to optimize protection and reduce RSV burden in infants.